CoronaryAtlas logo
CoronaryAtlas
Matrix Metalloproteinase-2
Pathway / Fibrous-cap degradation & rupture

Matrix Metalloproteinase-2

MMP2protein

MMP-2 degrades the fibrous cap and myocardial ECM, mediating plaque rupture and post-infarction ventricular remodeling.

Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencehigh
RationaleECM degradation in plaque rupture and post-MI remodeling; s3 anchor.
Also acts inMyocardial injury
Druggability
DruggableYes
Known drugs / candidates3
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000087245

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
50
A — assay feasibility
72
E — evidence strength
75
T1DI (composite)
32
Specificity differential (R−C)+16.7
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 1
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 1
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 4/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 20 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(13)